Navigation Links
Repligen Reports First Quarter Fiscal Year 2010 Financial Results
Date:8/6/2009

enefit) provision - 210,000 ---- ------- Net income (loss) $(1,105,980) $8,278,828 =========== ========== Earnings (loss) per share: Basic $(0.04) $0.27 ====== ===== Diluted $(0.04) $0.26 ====== ===== Weighted average shares outstanding: Basic 30,742,212 31,152,556 ========== ========== Diluted 30,742,212 31,585,112 ========== ========== Balance Sheet Data: June 30, 2009 March 31, 2009 ------------- -------------- Cash, cash equivalents and marketable securities* $61,969,507 $63,960,564 Working capital 50,327,307 50,234,803 Total assets 71,455,664 73,754,742 Long-term obligations 73,249 82,398 Accumulated deficit (114,963,241) (113,857,261) Stockholders' equity 68,258,162 69,123,431 *does not include restricted cash

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are c
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Immunosyn,Corporation (OTC Bulletin Board: IMYN), a biotechnology firm ... rights to,the biopharmaceutical SF-1019 from its affiliate Argyll ... ending March 31, 2008., For the quarter ... general and administrative expenses and $13,393.00 in interest ...
... 16 InterMune, Inc.,(Nasdaq: ITMN ) today announced ... of InterMune, will present at the Citigroup 2008,Global Healthcare ... 1:30 p.m. EDT., To access a live audio ... log on to the investor relations page of InterMune,s,corporate ...
... May 16 StemCyte Inc. today announced,that Chief Scientific ... a focus on the StemCyte,s Indian joint venture at ... will present during the session on "Stem Cells - ... on Saturday, May 17. His,presentation will include information about ...
Cached Biology Technology:Immunosyn Corporation Files 10-Q 2Immunosyn Corporation Files 10-Q 3StemCyte Chief Scientific Officer to Present Company Overview with Focus on Indian Joint Venture at TiEcon 2008 2
(Date:7/9/2014)... one gene for another in a line of living ... reality within this decade. As with any new technology, ... disease-causing genes in humans, for example--as well as questions ... of those concerns to rest: using gene-editing techniques on ... in the cells. The new results were published July ...
(Date:7/9/2014)... As climate change shifts the geographic ranges in which ... it has on their parasites. Does an increased range ... as well? , Not necessarily, says a team of ... Armand Kuris. In a study published in the ... that for some species, the opposite may happen: Hosts ...
(Date:7/9/2014)... Fla. (July 9, 2014) Emerging fungal pathogens ... other parasitic group, causing population declines of amphibians, ... the University of South Florida published in the ... can acquire behavioral or immunological resistance to a ... declines. , "Acquired resistance is important because ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2
... are developing new technologies that combine a laser ... particles such as bacteria, viruses and DNA for ... to food safety. The technologies could bring ... or miniature instruments that perform measurements normally requiring ...
... have no way of predicting which threatened miscarriages will ... we are unable to target attempts to rescue the ... counselling," she said. "This has led to wasteful and ... hospital admissions for bed rest, sexual abstinence, low dose ...
... For the first time, fertility experts have shown that, ... poor oral health can have a significant effect on the ... meeting of the European Society of Human Reproduction and Embryology ... of the same order of magnitude as the effect of ...
Cached Biology News:Laser, electric fields combined for new 'lab-on-chip' technologies 2Laser, electric fields combined for new 'lab-on-chip' technologies 3Researchers can predict accurately the outcome of pregnancies threatening to miscarry 2Gum disease can increase the time it takes to become pregnant 2Gum disease can increase the time it takes to become pregnant 3
Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form....
Antibody specific for phosphorylattion of histone H3 that occurs during mitosis. Rabbit polyclonal serum. Antigen: Synthetic peptides derived from histone H3, phosphorylated at serines 10 or 28...
5 minutes from gel band to purified DNA...
...
Biology Products: